MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

MDT

88.75

+2.73%↑

A

116.89

+2.76%↑

VEEV

166.33

-3.59%↓

HQY

81.95

+1.22%↑

TLRY

6.75

+4.65%↑

Search

Heron Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

0.82 5.13

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.78

Max

0.84

Galvenie mērījumi

By Trading Economics

Ienākumi

15M

-3M

Pārdošana

2.4M

41M

EPS

-0.02

Peļņas marža

-7.278

Darbinieki

128

EBITDA

13M

-792K

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+469.62% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 5. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-65M

153M

Iepriekšējā atvēršanas cena

-4.31

Iepriekšējā slēgšanas cena

0.82

Ziņu noskaņojums

By Acuity

52%

48%

285 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Heron Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. apr. 17:26 UTC

Galvenie ziņu notikumi

EIA Raises Oil-Price Forecasts as War in Middle East Continues

2026. g. 7. apr. 23:55 UTC

Tirgus saruna

Genesis Energy Signals Higher Dividend Payout Ratios -- Market Talk

2026. g. 7. apr. 23:47 UTC

Tirgus saruna
Galvenie ziņu notikumi

Market Talk Roundup: Latest on U.S. Politics

2026. g. 7. apr. 23:47 UTC

Tirgus saruna
Galvenie ziņu notikumi

Precious Metals Rise, Boosted by Dollar Weakness, Lower Treasury Yields -- Market Talk

2026. g. 7. apr. 23:44 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Rallies as Trump Remarks Send Oil Prices Lower -- Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 7. apr. 23:42 UTC

Tirgus saruna

Nikkei Likely to Rise After Trump Agrees to Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:37 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Futures Fall After Trump Agrees to Two-Week Cease-Fire With Iran -- Market Talk

2026. g. 7. apr. 23:15 UTC

Tirgus saruna
Galvenie ziņu notikumi

Markets Will Want Fast Evidence That Ships Are Moving -- Market Talk

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Spot Gold Rises 2.5%, Spot Silver Climbs 4.9%

2026. g. 7. apr. 23:04 UTC

Galvenie ziņu notikumi

Precious Metals Rise After Trump Agrees to Ceasefire With Iran

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. apr. 23:03 UTC

Tirgus saruna

Middle East Ceasefire Triggers Australian Dollar Rally -- Market Talk

2026. g. 7. apr. 23:01 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Falls 13.7% to $97.47 per Barrel

2026. g. 7. apr. 22:58 UTC

Galvenie ziņu notikumi

Front-Month Crude Oil Futures Slide After Trump Agrees to Cease-Fire With Iran

2026. g. 7. apr. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Telefónica Sells All Shares in Pegaso PCS, Celular de Telefonía

2026. g. 7. apr. 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 7. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 7. apr. 19:45 UTC

Tirgus saruna

Treasury Yields Mixed as Investors Brace for Iran Deadline -- Market Talk

2026. g. 7. apr. 19:17 UTC

Galvenie ziņu notikumi

The Risks to the Gulf Region's Oil Are Immense. Are Markets Shrugging Them Off? -- Barrons.com

2026. g. 7. apr. 19:16 UTC

Tirgus saruna

Cold Shot Helps U.S. Natural Gas Futures Settle Higher -- Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 7. apr. 19:07 UTC

Tirgus saruna

Oil Futures Mixed Ahead of Trump's Iran Deadline -- Market Talk

2026. g. 7. apr. 18:41 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold: Total of 149.6M Common Shrs, Representing 75.31% of Votes Attached to All Outstanding Common Shrs, Were Voted >ELD.T

2026. g. 7. apr. 18:40 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Holders Voted to Approve Issuance of Common Shrs in Connection With Proposed Plan of Arrangement With Foran Mining >ELD.T

2026. g. 7. apr. 18:39 UTC

Iegādes, apvienošanās, pārņemšana

Eldorado Gold Reports Voting Results From Special Meeting of Hldrs

2026. g. 7. apr. 18:24 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 17:08 UTC

Tirgus saruna

Latin America Less Exposed to Crude Supply Disruptions -- Market Talk

2026. g. 7. apr. 16:21 UTC

Galvenie ziņu notikumi

Defense Stocks Can't Get a Boost From Iran War Escalations. What Would Move Them. -- Barrons.com

2026. g. 7. apr. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Heron Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

469.62% augšup

Prognoze 12 mēnešiem

Vidējais 4.5 USD  469.62%

Augstākais 6 USD

Zemākais 3 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Heron Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

2

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

2.0001 / 2.42Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

285 / 349 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat